| Methods |
RCT. Placebo controlled, crossover design.
Double‐blind.
Masking of assessors not stated. |
| Participants |
19 female patients
Inclusion criteria: Cystometric evidence of detrusor instability; absent or minimal bladder suspension defect; max urinary flow above 15ml/s; residual <50ml; MSU <100,000 colonies/ml; no bladder stone or tumour by cystoscopy.
Exclusion criteria: Severe heart failure or glaucoma. Neurological disease or detrusor sphincter dyssynergia. Drugs taken during study affecting autonomous nervous system or smooth muscles. |
| Interventions |
Treatment 1: emepronium bromide 200mg qid
Treatment 2: flavoxate chloride 200mg qid
Treatment 3: placebo
Each treatment period 14 days with 7 day washout between. |
| Outcomes |
Patient drug preferences.
Number of leakage episodes, frequency of micturition, nocturia.
Adverse events. |
| Notes |
Data not in useable form for this review.
Company support declared. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
